Authors


Charles G. Drake, MD, PhD

Latest:

Investigating Immunotherapy Treatment in Renal Cell Carcinoma

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.


Charles J. Ryan, MD

Latest:

Use of ARN-509 in Prostate Cancer

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.


Charles L. Shapiro, MD

Latest:

The Results of the IBIS II Trial

Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.


Charles M. Perou, PhD

Latest:

Dr. Charles M. Perou on the Evolution of Precision Medicine in Breast Cancer

​Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers.


Charles M. Rudin, MD, PhD

Latest:

Stimulating the Immune System With Coxsackievirus in Advanced Cancer Patients

Charles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.


Charles Perou, PhD

Latest:

Dr. Charles Perou on Molecular Differences in Lobular Breast Cancer

Perou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.



Charles S. Fuchs, MD, MPH

Latest:

The Future Treatment Landscape of Gastric Cancer

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses what he envisions for the future treatment landscape of gastric cancer.



Charu Aggarwal, MD, MPH

Latest:

Closing Thoughts on Recent Data in Non–Small Cell Lung Cancer

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.


Chase Doyle

Latest:

Use of Anthracyclines Plus Taxanes Found to be Beneficial in Early, HER2-Negative Breast Cancer

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.


Chau Dang, MD

Latest:

Case 2: Safety Considerations in the Use of T-DXd for HER2+ mBC

A key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.


Chelsea LoCascio

Latest:

CDK4&6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

Denise A. Yardley, MD, discusses the promise of CDK4&6 inhibitors in estrogen receptor (ER)-positive breast cancer, as well as the potential with immunotherapy agents. 


Cheryl Alkon

Latest:

Effective Options Arise for Patients With ALK-Positive NSCLC

New treatments that are currently in development have begun to show promise for patients diagnosed with ALK-positive non-small-cell lung cancer (ALK+ NSCLC), a subset of patients who have historically faced poor outcomes.


Cheryl Zigrand

Latest:

Searching for Positives in Triple-Negative Breast Cancer

Treatments for triple-negative breast cancer (TNBC) have made significantly less progress in comparison with other subtypes.


Chiara Cremolini, MD

Latest:

FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer

Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.


Christian Jackisch, MD, PhD

Latest:

Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer

Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.


Christiane K. Kuhl, MD

Latest:

Dr. Christiane Kuhl Discusses Breast MRI Screening of Women at Average Risk of Breast Cancer

Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH University of Aachen, discusses an observational cohort study looking at breast MRI screening of women at average risk of breast cancer.


Christiane Kuhl, MD

Latest:

Dr. Christiane Kuhl on the Overdiagnosis of Breast Cancer

Christiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.


Christin L. Melton

Latest:

Targeted Therapies End the Dry Spell in AML Drug Development

Targeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia, representing the first therapeutic advances for AML in decades.


Christin L. Melton, ELS

Latest:

Recent Studies Point to a Greater Role for PARP Inhibitors in Solid Tumors

The early development of PARP inhibitors in 2003 focused on their use in combination with cytotoxic chemotherapy agents, but this was eventually abandoned because of excess toxicity.


Christin Melton

Latest:

Epidemic in Sex-Related Oral Cancer Highlights Need for Guidelines

Over the past few decades, the annual incidence of OPSCC has increased sharply in several countries, including in the United States.


Christin Melton, ELS

Latest:

Study Validates Noninvasive Urinary Cell-Free DNA Assay for Urothelial Bladder Cancer

A recent study has shown that extracting cell-free DNA from urine is a highly effective technique for analyzing the genetic profile of urothelial bladder cancers.


Christin Melton, ELS, CMPP

Latest:

Whole-Genome Sequencing Identifies New Targets in Pancreatic Cancer

A research team led by investigators at the University of Texas Southwestern Medical Center in Dallas has published a study in Nature Communications identifying several new genetic mutations in pancreatic ductal adenocarcinoma.


Christina Baik, MD, MPH

Latest:

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.


Christina Izzo

Latest:

Improving Quality of Life in Cervical Cancer Survivors

A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.



Christina M. Annunziata, MD, PhD

Latest:

A Study of Olaparib and Cediranib in Ovarian Cancer

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.


Christina T. Logudice

Latest:

New Device Treats Nonmelanoma Skin Cancer Noninvasively

According to the Skin Cancer Foundation, more than 3.5 million cases of nonmelanoma skin cancers (NMSCs) are treated in the United States annually, making it the most commonly encountered malignancy.


Christina T. Loguidice

Latest:

Study Suggests Panurothelial Carcinoma Warrants More Aggressive Surgical Treatment

A study published in Scientific Reports by researchers from China indicates panurothelial carcinoma (panUCC) has a high risk of recurring, progressing, and disseminating after conservative surgery, leading to poor outcomes.